ABSTRACT
OBJECTIVE: To discuss the influencing factors of perinatal outcomes in preeclampsia. METHODS: Statistically the single factor analysis and multivariate logistic regression analysis were performed for 448 preeclamptic women. RESULTS: There were 94 cases (21.0%) with had perinatal outcomes in 448 preeclamptic women, among which there were 41 perinatal death cases (9.2%). Single analyses showed that Onset gestation weeks, labor gestation weeks, subjective symptoms, convulsion, proteinuria degrees, edema, systolic pressure, diastolic pressure, white blood count, granulocyte count, urine protein quantity, plasma-albumin, lactate dehydrogenase, creatinine, antenatal care frequencies, hypertension (gestation weeks) and edema (gestation weeks) were correlated to bad perinatal Outcomes (P < 0.05). The logistic regression screened out such factors as labor gestation weeks (OR 0.583, 95% CI: 0.367-0.926), subjective symptoms (OR 9.315, 95% CI: 1.500-57.833) and proteinuria degrees (OR 3.394, 95% CI: 1.226-9.397), which would influence perinatal outcome in preeclampais. CONCLUSION: Regular antenatal cares and extending gestation weeks may improve the perinatal Outcome in preeclampais.
Subject(s)
Pre-Eclampsia/epidemiology , Pregnancy Outcome , Female , Gestational Age , Humans , Logistic Models , Multivariate Analysis , Pregnancy , Prenatal CareABSTRACT
OBJECTIVE: To test the hypothesis that homocysteine can decrease MMP-2 and MMP-9 expression in cultured trophoblasts of early pregnancy and that homocysteine can prevent trophoblasts invasion in the early stage of preeclampsia. METHODS: Cytotrophoblasts from early pregnancy were isolated and cultured. Trophoblasts were treated with or without Hcy (1 mmol/L) for 48 hour, and real time RT-PCR and gelatin zymography were used to quantify the mRNA and protease activity of MMP-2, -9. RESULTS: Treatment with Hcy (1 mmol/L) induced a decrease in MMP-2 mRNA by 21% and MMP-9 mRNA by 11%. At protein level MMP-2 expression decreased 14% and MMP-9 expression decreased 52% compared with control. CONCLUSIONS: Homocysteine can decrease MMP-2, -9 expression in trophoblasts of early pregnancy and influence its invasion process.
Subject(s)
Homocysteine/pharmacology , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 9/biosynthesis , Trophoblasts/drug effects , Adult , Cells, Cultured , Female , Gestational Age , Humans , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/genetics , Pre-Eclampsia/metabolism , Pre-Eclampsia/pathology , Pregnancy , Pregnancy Trimester, First , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Trophoblasts/cytology , Trophoblasts/metabolismABSTRACT
OBJECTIVE: To study the possible relationships between expression of matrix metalloproteinase (MMP) 2, 9 and the pathogenesis of preeclampsia in which trophoblast invasion is impaired. METHODS: MMP-2, 9 expression were detected by immunohistochemistry streptavidin-biotin complex (SABC) method in 20 normal term placentae and 20 preeclampsia placentae, respectively. In addition, mRNAs for MMP-2, 9 were analyzed by real time PCR in both groups. RESULTS: The intensities of both MMP-2 and MMP-9 immunostaining in preeclampsia placentae were significantly declined compared to those of normal term placentae (P < 0.05). By using 2(-DeltaDeltaCt) as a relatively quantitative assay, mRNA expression of MMP-2 was significantly higher in 10 normal placentae than those in 13 preeclampsia placentae (7.6 +/- 2.8 vs 5.6 +/- 1.5, P < 0.05). Expression of MMP-9 mRNA was also significantly higher in normal placentae than those in preeclampsia placentae (2.2 +/- 2.6 vs -0.9 +/- 2.0, P < 0.05). Whereas, mRNA expression of MMP-2 was higher compared to MMP-9 in normal term placentae (P < 0.05). CONCLUSION: The decreased expression of MMP-2 and MMP-9 in preeclampsia placentae may lead to impaired invasion of trophoblast cells, causing abnormal placentation and occurrence of preeclampsia.
